Dr Reddy's Laboratories Ltd filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, reporting a standalone turnover of ₹20,102 crore. The pharmaceutical major committed to achieving net zero greenhouse gas emissions across its value chain by FY2045, a target approved by the Science Based Targets initiative (SBTi) during FY26. Additionally, the company aims for carbon neutrality in its direct operations by 2030. Exports contributed 68% of the total turnover, while 71% of input materials were sourced locally from within India.

The company detailed its environmental performance, highlighting the elimination of coal from its operational fuel mix. In FY26, Dr Reddy's completed a multi-year fuel transition, converting all primary operating boilers across its manufacturing network to biomass, briquettes, or piped natural gas. This initiative contributed to a reduction in Scope 1 and Scope 2 emissions. The company reported a decrease in total energy consumption to 46,49,832 GJ from 47,53,823 GJ in the previous year, with energy intensity improving to 13.8 GJ/₹ Million.

Financial and Operational Metrics

Dr Reddy's operations span pharmaceutical development, manufacturing, and sales, which account for 100% of its turnover. The report indicates that 71.5% of procurement was directly sourced from within the country, while 5.3% was sourced directly from MSMEs or small producers.

Environmental Performance

Water consumption stood at 19,56,215 kilolitres, with a water intensity of 5.82 KL/₹ Million. The company has implemented Zero Liquid Discharge facilities across 16 global manufacturing facilities. The report also noted that Dr Reddy's is a water-positive company since FY2023.

Social and Governance Highlights

The company employed 36,726 permanent and other-than-permanent employees as of the end of FY26. Women constituted 23.8% of the total workforce. The report noted that 43% of new launches in priority markets were first-to-market, exceeding the company's target of 40% by 2030. Dr Reddy's has set a goal to serve 1.5 billion patients by 2030. Regarding governance, the company stated that it received no fines or penalties from regulatory agencies during the financial year.

Dr Reddy's Laboratories has scheduled its 42nd Annual General Meeting (AGM) for Thursday, July 23, 2026, at 11.00 a.m. IST via video conference. The Board of Directors has recommended a final dividend of Rs 8 per equity share of face value Rs 1 each for the financial year ended March 31, 2026. Shareholders must ensure their bank details are updated to receive the dividend payment electronically on or before July 30, 2026.

The company has fixed Friday, July 10, 2026, as the record date to determine the entitlement of members to the final dividend, subject to approval at the AGM. The notice for the AGM and the Integrated Annual Report for FY26 will be sent electronically to shareholders who have registered their email addresses with the company or depository participants. Physical copies will not be dispatched.

Shareholders can participate in the AGM only through video conferencing or other audio-visual means, and their attendance will count towards the quorum. A remote e-voting facility will be available for members to cast their votes prior to or during the meeting. Detailed procedures for e-voting and joining the virtual meeting will be provided in the notice.

The company has outlined tax deduction at source (TDS) regulations applicable to dividend income effective from April 1, 2026. For resident shareholders with a valid PAN, the TDS rate is 10%, while it rises to 20% for those without a valid PAN or with an inoperative PAN. No tax will be deducted if the total dividend income does not exceed Rs 10,000 during the tax year 2026-27.

Non-resident shareholders will be subject to TDS at 20% plus applicable surcharge and cess, unless they opt for benefits under the Double Tax Avoidance Treaty (DTAA). To avail DTAA benefits, non-resident shareholders must submit a self-attested Tax Residency Certificate, PAN details, and Form 41. Shareholders must submit all necessary documents to the Registrar and Transfer Agent by 11.59 pm IST on June 30, 2026, to ensure the correct tax rate is applied.